Background Clinical remission has emerged as an important treatment goal in severe
asthma; however, studies have reported variable attainment due to differences in study …

Asthma, allergic rhinitis, and food allergy are common allergic diseases, yet adherence to
many management options remains poor, leading to worse health outcomes and financial …

Rationale: There are no direct comparisons of sotatercept to add-on therapies approved for
PAH. Objective: This study aimed to compare the efficacy and safety of add-on sotatercept …

(1) Background: Over the past 20 years, monoclonal antibodies have been developed for
the treatment of severe asthma, with numerous randomised controlled trials (RCTs) …

Abstract Purpose of Review To assess the effects of tezepelumab on quality of life (QoL) in
patients with moderate-to-severe, uncontrolled asthma. Recent Findings Tezepelumab …

For clinicians involved in improving healthcare for patients with allergic and immunologic
conditions, advocacy on a broader level through public outreach is key to advancing value …

Introduction The hallmark of most patients with severe asthma is type 2 inflammation, driven
by innate and adaptive immune responses leading to either allergic or non-allergic …

Background: Six biologic agents are now approved for patients with severe asthma. This
meta-analysis aimed to assess the efficacy and safety of licensed biologic agents in patients …

Background: Severe asthma is a challenging condition that often resists traditional
treatments and requires high-dose inhaled corticosteroids and other controllers to manage …

Background Despite limited breakthroughs in COPD pharmacotherapy, recent trials have
shown promising results for biologics in COPD patients. However, robust evidence synthesis …